KR100691572B1 - 세포로의 치료제 전달을 증진시키는 조성물 및 방법 - Google Patents

세포로의 치료제 전달을 증진시키는 조성물 및 방법

Info

Publication number
KR100691572B1
KR100691572B1 KR1020007000178A KR20007000178A KR100691572B1 KR 100691572 B1 KR100691572 B1 KR 100691572B1 KR 1020007000178 A KR1020007000178 A KR 1020007000178A KR 20007000178 A KR20007000178 A KR 20007000178A KR 100691572 B1 KR100691572 B1 KR 100691572B1
Authority
KR
South Korea
Prior art keywords
group
gene
compound
hexose
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007000178A
Other languages
English (en)
Korean (ko)
Other versions
KR20010021620A (ko
Inventor
하이드런 엥글러
타타나할리 엘. 나가부스한
스티븐 케네쓰 영스터
Original Assignee
캔지, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캔지, 인크. filed Critical 캔지, 인크.
Publication of KR20010021620A publication Critical patent/KR20010021620A/ko
Application granted granted Critical
Publication of KR100691572B1 publication Critical patent/KR100691572B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020007000178A 1997-07-08 1998-07-08 세포로의 치료제 전달을 증진시키는 조성물 및 방법 Expired - Fee Related KR100691572B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/889,355 US7002027B1 (en) 1996-01-08 1997-07-08 Compositions and methods for therapeutic use
US8/889,355 1997-07-08
US08/889,355 1997-07-08
PCT/US1998/014241 WO1999002191A1 (en) 1997-07-08 1998-07-08 Compositions and methods for enhancing delivery of therapeutic agents to cells

Publications (2)

Publication Number Publication Date
KR20010021620A KR20010021620A (ko) 2001-03-15
KR100691572B1 true KR100691572B1 (ko) 2007-03-12

Family

ID=25394956

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007000178A Expired - Fee Related KR100691572B1 (ko) 1997-07-08 1998-07-08 세포로의 치료제 전달을 증진시키는 조성물 및 방법

Country Status (20)

Country Link
US (3) US7002027B1 (https=)
EP (2) EP2106807B1 (https=)
JP (2) JP4460148B2 (https=)
KR (1) KR100691572B1 (https=)
AR (1) AR016312A1 (https=)
AT (2) ATE434448T1 (https=)
AU (1) AU774338B2 (https=)
CA (1) CA2294709C (https=)
CY (1) CY1109367T1 (https=)
DE (2) DE69840932D1 (https=)
DK (1) DK1011733T3 (https=)
ES (2) ES2328094T3 (https=)
HU (1) HUP0002683A3 (https=)
IL (1) IL133929A0 (https=)
MY (1) MY138257A (https=)
NZ (1) NZ502060A (https=)
PT (1) PT1011733E (https=)
TW (1) TW490306B (https=)
WO (1) WO1999002191A1 (https=)
ZA (1) ZA986003B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
EP1070047A2 (en) 1998-04-08 2001-01-24 Celltech Chiroscience Limited Lipids
ES2745068T3 (es) * 2001-12-20 2020-02-27 Merck Sharp & Dohme Composiciones de SYN3 y métodos
JP2007526219A (ja) * 2003-06-04 2007-09-13 カンジ，インコーポレイテッド トランスフェクション薬剤
US7355056B2 (en) * 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
CA2548100C (en) * 2003-12-10 2015-03-24 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US8716021B2 (en) * 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
US20110071100A1 (en) * 2008-05-05 2011-03-24 Tiltan Pharma Ltd. Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US20120147800A1 (en) * 2010-12-10 2012-06-14 Minyoung Park Power management in a wireless network having stations with different power capabilities
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service
WO2026077967A1 (en) 2024-10-08 2026-04-16 Ferring International Center Sa Method for making syn3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010038A1 (en) * 1997-08-29 1999-03-04 Mulholland S Grant Catheter having plurality of distal inflatable retention means

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5120316A (en) 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
NZ240846A (en) * 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
DE69233725T2 (de) 1991-06-28 2009-02-12 The Regents Of The University Of Michigan, Ann Arbor Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
DK0636028T3 (da) 1992-04-03 2004-07-12 Univ California Selvorganiserende polynucleotidleveringssystem omfattende et amfipatisk kationisk peptid
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
JPH07109983A (ja) 1993-10-13 1995-04-25 Nippondenso Co Ltd スクロール型圧縮機
DE69431959T2 (de) 1993-10-15 2003-11-06 Cytrx Corp Therapeutische abgabesysteme und verfahren für ihre verwendung
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
AU6600396A (en) * 1995-07-28 1997-02-26 David E. Kohne Method for enhancing chemiluminescence
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5671110A (en) 1996-01-23 1997-09-23 Oneac Corporation Ground skew protection method and apparatus
US6938069B1 (en) * 2000-03-18 2005-08-30 Computing Services Support Solutions Electronic meeting center
ES2745068T3 (es) 2001-12-20 2020-02-27 Merck Sharp & Dohme Composiciones de SYN3 y métodos
KR100499787B1 (ko) 2002-11-29 2005-07-07 인티그런트 테크놀로지즈(주) 스위치 모드 동작을 하는 선형성이 우수한 광대역 가변이득 증폭기
JP2007526219A (ja) 2003-06-04 2007-09-13 カンジ，インコーポレイテッド トランスフェクション薬剤
US7355056B2 (en) 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
WO2004108898A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
CA2548100C (en) 2003-12-10 2015-03-24 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010038A1 (en) * 1997-08-29 1999-03-04 Mulholland S Grant Catheter having plurality of distal inflatable retention means

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Journal of Pharmaceutics, 제53권, 제227면 내지 제235면 *

Also Published As

Publication number Publication date
JP2010070565A (ja) 2010-04-02
HUP0002683A2 (hu) 2000-12-28
DK1011733T3 (da) 2009-09-28
US7538093B2 (en) 2009-05-26
EP1011733A1 (en) 2000-06-28
IL133929A0 (en) 2001-04-30
ES2328094T3 (es) 2009-11-06
CA2294709A1 (en) 1999-01-21
ATE497786T1 (de) 2011-02-15
AU774338B2 (en) 2004-06-24
DE69842133D1 (de) 2011-03-24
AU8390198A (en) 1999-02-08
MY138257A (en) 2009-05-29
US20060199782A1 (en) 2006-09-07
US8022044B2 (en) 2011-09-20
DE69840932D1 (de) 2009-08-06
CA2294709C (en) 2010-05-11
US7002027B1 (en) 2006-02-21
HK1028961A1 (en) 2001-03-16
CY1109367T1 (el) 2014-07-02
US20100028431A1 (en) 2010-02-04
AR016312A1 (es) 2001-07-04
JP4460148B2 (ja) 2010-05-12
EP1011733A4 (en) 2004-09-29
TW490306B (en) 2002-06-11
WO1999002191A1 (en) 1999-01-21
JP2001509492A (ja) 2001-07-24
ATE434448T1 (de) 2009-07-15
ZA986003B (en) 1999-01-28
KR20010021620A (ko) 2001-03-15
HK1134025A1 (en) 2010-04-16
NZ502060A (en) 2003-01-31
EP2106807B1 (en) 2011-02-09
EP2106807A1 (en) 2009-10-07
PT1011733E (pt) 2009-09-15
HUP0002683A3 (en) 2005-09-28
EP1011733B1 (en) 2009-06-24
ES2362027T3 (es) 2011-06-27

Similar Documents

Publication Publication Date Title
KR100691572B1 (ko) 세포로의 치료제 전달을 증진시키는 조성물 및 방법
US6165779A (en) Compositions and methods for therapeutic use
Zabner et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo.
US6392069B2 (en) Compositions for enhancing delivery of nucleic acids to cells
EP1629085A2 (en) Transfection agents
Ziady et al. Non-viral gene transfer therapy for cystic fibrosis
Preuss et al. Comparison between the interactions of adenovirus-derived peptides with plasmid DNA and their role in gene delivery mediated by liposome–peptide–DNA virus-like nanoparticles
US6221848B1 (en) Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
MXPA00000306A (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
HK1134025B (en) Compositions and kits for enhancing delivery of therapeutic agents to cells
HK1028961B (en) Compositions and methods for enhancing delivery of therapeutic agents to cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20130130

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20140129

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150301

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150301